Veracyte (VCYT) – Business Wire
-
Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
-
New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
-
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
-
Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
-
Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
-
Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
-
Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
-
Veracyte Completes Acquisition of C2i Genomics
-
Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform
-
Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
-
Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress
-
Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules
-
Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023
-
Veracyte Announces Third Quarter 2023 Financial Results
-
Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally
-
Veracyte to Participate in the Stephens Annual Investment Conference
-
Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development
-
Veracyte to Release Third Quarter 2023 Financial Results on November 7, 2023
-
New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracyte’s Envisia Genomic Classifier for Patients with Interstitial Lung Disease
-
New Data from Phase 3 Trial Further Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier
-
New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracyte’s Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer
-
Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023
-
Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer
-
Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting
-
Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Company’s Tests
-
Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies
-
Veracyte to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
-
Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer
-
Veracyte Earns Top Workplace Awards in the San Francisco Bay Area and San Diego
-
Veracyte Announces Second Quarter 2023 Financial Results
-
Study Published in JNCI Cancer Spectrum Demonstrates Real-World Utility of Veracyte’s Decipher Prostate Genomic Classifier in Prostate Cancer Treatment
-
Veracyte to Release Second Quarter 2023 Financial Results on August 8, 2023
-
New Data Suggest Veracyte’s Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer
-
Veracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023
-
New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracyte’s Decipher GRID To Help Advance Molecular Understanding of Prostate Cancer
-
New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
-
Veracyte to Participate in Upcoming Investor Conferences
-
Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer
-
Veracyte Announces First Quarter 2023 Financial Results
-
New Data Being Presented at AACE 2023 Help Elucidate Cancer Risk of TERT Promoter Gene Mutations in Patients with Indeterminate Thyroid Nodules
-
New Data Published In Cancer Suggest Decipher GRID-Derived Gene Expression Signature Could Enable More Personalized Treatment for Prostate Cancer Patients
-
Data Published in "The Red Journal” Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy in Men with Intermediate-Risk Prostate Cancer
-
Three Abstracts Focusing on the Clinical Utility of Veracyte’s Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International Conference
-
Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier
-
Veracyte Announces Five Abstracts Providing Molecular Insights Into Prostate and Other Cancers To Be Presented at the 2023 ASCO Annual Meeting
-
New Data Reinforce Ability of Veracyte’s Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification
-
Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023
-
Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting
-
Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Company’s Multi-Omics Capabilities and Tools for Biopharma Partners
-
Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank
Back to VCYT Stock Lookup
